Xeris Biopharma (XERS) Projected to Post Quarterly Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Xeris Biopharma to post earnings of ($0.08) per share and revenue of $58.54 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Xeris Biopharma Trading Down 3.7 %

XERS opened at $3.69 on Tuesday. The firm has a market capitalization of $550.11 million, a PE ratio of -8.20 and a beta of 2.61. Xeris Biopharma has a 12-month low of $1.69 and a 12-month high of $4.10. The firm has a 50 day moving average of $3.53 and a two-hundred day moving average of $3.22.

Wall Street Analyst Weigh In

A number of analysts have recently commented on XERS shares. HC Wainwright boosted their price objective on Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th. Piper Sandler lowered Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research note on Monday, November 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.